Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Si Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6652-0629; OpenAlex author ID A5030036878, A5078370650, A5137177048. Sources: ClinicalTrials.gov.

Their work

Papers
123 (first author 21, last author 41)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
149
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 4 papers · 2015: 2 papers · 2016: 8 papers · 2017: 7 papers · 2018: 9 papers · 2019: 13 papers · 2020: 13 papers · 2021: 17 papers · 2022: 5 papers · 2023: 12 papers · 2024: 13 papers, 1 trial · 2025: 10 papers · 2026: 5 papers

Papers 50 of 123

  1. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.05.012↗
  2. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.08.012↗
  3. Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73702-z↗
  4. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2025.09.032↗
  5. Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibi… Last author DOI 10.1136/gutjnl-2025-336235↗
  6. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Co-author DOI 10.1016/j.tranon.2025.102346↗
  7. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364↗
  8. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  9. SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. Co-author DOI 10.1097/cm9.0000000000003640↗
  10. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  11. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Last author DOI 10.1136/gutjnl-2024-332782↗
  12. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334361↗
  13. Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarci… Co-author DOI 10.1186/s12916-025-04078-y↗
  14. Tumor Volume Evaluation is a Superior Predictor of Prognosis Compared to RECIST in Metastatic Pancreatic Ductal Adenocarcinoma Undergoing Immunochemotherapy Co-author DOI 10.21203/rs.3.rs-7634457/v1↗
  15. The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Last author DOI 10.7150/thno.111180↗
  16. Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. Last author DOI 10.1007/s13402-024-01022-9↗
  17. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.csbj.2024.04.021↗
  18. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ebiom.2024.105098↗
  19. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Last author DOI 10.1016/j.redox.2024.103200↗
  20. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.019↗
  21. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Last author DOI 10.1038/s41416-024-02631-9↗
  22. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Last author DOI 10.1038/s41419-024-06984-0↗
  23. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  24. NLRP4 drives olaparib resistance in pancreatic cancer. Last author DOI 10.1080/27694127.2024.2422729↗
  25. PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells. Last author DOI 10.1126/sciadv.adk6633↗
  26. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Last author DOI 10.1158/0008-5472.can-23-3596↗
  27. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Co-author DOI 10.1186/s12885-024-11842-5↗
  28. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12916-024-03581-y↗
  29. The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG. First author DOI 10.1007/s00330-023-09445-y↗
  30. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Last author DOI 10.1016/j.csbj.2023.03.037↗
  31. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003↗
  32. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2022.101561↗
  33. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Last author DOI 10.1016/j.tranon.2023.101692↗
  34. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Last author DOI 10.1016/j.xcrm.2023.101234↗
  35. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2022-329349↗
  36. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… First author DOI 10.1186/s13063-023-07456-0↗
  37. Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Last author DOI 10.1245/s10434-023-13102-5↗
  38. ASO Author Reflections: Prognostic Value of Tumor Deposits in Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-023-13109-y↗
  39. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Co-author DOI 10.3390/curroncol30030228↗
  40. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms24043476↗
  41. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121306↗
  42. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Last author DOI 10.1016/j.csbj.2022.07.029↗
  43. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. First author DOI 10.1038/s41388-022-02306-w↗
  44. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/bib/bbab388↗
  45. The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2022/4148805↗
  46. Emerging roles of the solute carrier family in pancreatic cancer. Last author DOI 10.1002/ctm2.356↗
  47. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-021-03866-y↗
  48. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Co-author DOI 10.1016/j.hbpd.2020.12.020↗
  49. Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma". Last author DOI 10.1097/sla.0000000000003989↗
  50. Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines". Last author DOI 10.1097/sla.0000000000004291↗

Trials 1

  1. HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer Principal investigator NCT06217042↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 114 shared papers, 2012–2026 · strength 14.75
  2. Jin Xu · 88 shared papers, 2012–2026 · strength 10.53
  3. Jie Hua · 59 shared papers, 2018–2026 · strength 8.45
  4. Qingcai Meng · 57 shared papers, 2017–2026 · strength 7.38
  5. Chen Liang · 62 shared papers, 2016–2024 · strength 6.69
  6. Wei Wang · 26 shared papers, 2021–2025 · strength 4.08
  7. Miaoyan Wei · 20 shared papers, 2019–2026 · strength 3.27
  8. Bo Zhang · 20 shared papers, 2017–2024 · strength 2.86
  9. Rong Tang · 17 shared papers, 2020–2026 · strength 2.80
  10. Mingming Xiao · 11 shared papers, 2024–2026 · strength 2.66
  11. Quanxing Ni · 28 shared papers, 2014–2020 · strength 1.92
  12. Zhen Tan · 13 shared papers, 2019–2025 · strength 1.92
  13. Shunrong Ji · 23 shared papers, 2014–2025 · strength 1.46
  14. Yi Qin · 26 shared papers, 2013–2020 · strength 1.44
  15. Yiyin Zhang · 12 shared papers, 2018–2023 · strength 1.40
  16. Dingkong Liang · 21 shared papers, 2015–2019 · strength 1.35
  17. Xianjun Yu · 5 shared papers, 2019–2025 · strength 1.22
  18. Jiang Liu · 12 shared papers, 2015–2021 · strength 1.20
  19. Zeyin Rong · 7 shared papers, 2021–2026 · strength 1.19
  20. Wenyan Xu · 19 shared papers, 2014–2025 · strength 1.13
  21. Qiong Du · 5 shared papers, 2023–2026 · strength 0.99
  22. Xuhui Tong · 4 shared papers, 2024–2025 · strength 0.96
  23. Xiaomeng Liu · 7 shared papers, 2019–2023 · strength 0.95
  24. Yalan Lei · 4 shared papers, 2024–2025 · strength 0.87
  25. Mingwei Dong · 4 shared papers, 2023–2026 · strength 0.83

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.